Market capitalization | DKK8.61b |
Enterprise Value | DKK8.35b |
P/E (TTM) P/E ratio | 50.91 |
EV/FCF (TTM) EV/FCF | 54.87 |
EV/Sales (TTM) EV/Sales | 18.17 |
P/S ratio (TTM) P/S ratio | 18.73 |
P/B ratio (TTM) P/B ratio | 14.39 |
Dividend yield | 0.81% |
Last dividend (FY24) | DKK4.00 |
As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.
3 Analysts have issued a ChemoMetec forecast:
3 Analysts have issued a ChemoMetec forecast:
Dec '24 |
+/-
%
|
||
Revenue | 460 460 |
15%
15%
|
|
Gross Profit | 265 265 |
18%
18%
|
|
EBITDA | 224 224 |
13%
13%
|
EBIT (Operating Income) EBIT | 210 210 |
17%
17%
|
Net Profit | 169 169 |
18%
18%
|
In millions DKK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for fluid cell count and analysis. It operates through the following segments: Instruments, Consumer Goods, Service, and Others. The Instruments segment sells NucleoCounter NC-100, NC-200, NC250, and NC-3000. The Consumer Goods segment offers disposable cartridges, disposable analysis chambers, reagents, and test kits. The Service segment provides service packages and its corresponding guarantees. The Others segment offers measuring modules and accessories. The company was founded by Hans Martin Glensbjerg in 1977 and is headquartered in Allerod, Denmark.
Head office | Denmark |
CEO | Martin Behrens |
Employees | 174 |
Founded | 1997 |
Website | www.chemometec.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.